Anterogen Co., Ltd.
Anterogen is a KOSDAQ-listed (065660) stem-cell therapy company based in Seoul. Its product Cupistem has been approved in South Korea since 2012, and it is responding to US FDA chemistry and manufacturing questions on its candidate ANT301.
| Headquarters | Seoul, South Korea |
|---|---|
| Listing | KOSDAQ:065660 |
| Lead asset / stage | Cupistem Approved — South Korea |
| Latest event | Anterogen disclosed submission of its ANT301 CMC response to the US FDA on October 20. |